Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells

Scharf,Irene; Bierbaumer,Lisa; Huber,Heidemarie; Wittmann,Philipp; Haider,Christine; Pirker,Christine; Berger,Walter; Mikulits,Wolfgang

doi:10.3892/ol.2017.7605

Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells

Authors:
- Irene Scharf
- Lisa Bierbaumer
- Heidemarie Huber
- Philipp Wittmann
- Christine Haider
- Christine Pirker
- Walter Berger
- Wolfgang Mikulits
View Affiliations

Affiliations: Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, A‑1090 Vienna, Austria
Published online on: December 13, 2017 https://doi.org/10.3892/ol.2017.7605
Pages: 2441-2450

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genomic editing using the CRISPR/Cas9 technology allows selective interference with gene expression. With this method, a multitude of haploid and diploid cells from different organisms have been employed to successfully generate knockouts of genes coding for proteins or small RNAs. Yet, cancer cells exhibiting an aberrant ploidy are considered to be less accessible to CRISPR/Cas9‑mediated genomic editing, as amplifications of the targeted gene locus could hamper its effectiveness. Here we examined the suitability of CRISPR/Cas9 to knockout the receptor tyrosine kinase Axl in the human hepatoma cell lines HLF and SNU449. The genomic editing events were validated in two single cell clones each from putative HLF and SNU449 knockout cells (HLF‑Axl-‑1, HLF‑Axl‑‑2, SNU449‑Axl-‑1, SNU449‑Axl‑‑2). Sequence analysis of respective AXL loci revealed one to six editing events in each individual Axl‑ clone. The majority of insertions and deletions in the AXL gene at exon 7/8 resulted in a frameshift and thus a premature stop in the coding region. However, one genomic editing event led to an insertion of two amino acids resulting in an altered protein sequence rather than in a frameshift in the AXL locus of the SNU449‑Axl‑‑1 cells. Notably, while no Axl protein expression could be detected by immunoblotting in all four cell clones, both expression of total Axl as well as release of soluble Axl into the supernatant was observed by ELISA in incompletely edited SNU449‑Axl‑‑1 cells. Importantly, a comparative genomic hybridization array revealed comparable genomic changes in Axl knockout cells as well as in cells expressing Cas9 nickase without guide RNAs in SNU449 and HLF cells, indicating vast alterations in genomic DNA triggered by nickase. Together, these data show that the dynamics of CRISPR/Cas9 may cause incomplete editing events in cancer cell lines, as gene copy numbers vary based on genomic heterogeneity.

View Figures

View References

1	Davidson BL and Paulson HL: Molecular medicine for the brain: Silencing of disease genes with RNA interference. Lancet Neurol. 3:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
2	Xia H, Mao Q, Paulson HL and Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 20:1006–1010. 2002. View Article : Google Scholar : PubMed/NCBI
3	Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL and Paulson HL: Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA. 100:7195–7200. 2003. View Article : Google Scholar : PubMed/NCBI
4	Gaj T, Gersbach CA and Barbas CF III: ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
5	Liberali P, Snijder B and Pelkmans L: Single-cell and multivariate approaches in genetic perturbation screens. Nat Rev Genet. 16:18–32. 2015. View Article : Google Scholar : PubMed/NCBI
6	Joung JK and Sander JD: TALENs: A widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 14:49–55. 2013. View Article : Google Scholar : PubMed/NCBI
7	Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, et al: A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 29:143–148. 2011. View Article : Google Scholar : PubMed/NCBI
8	Harrison MM, Jenkins BV, O'Connor-Giles KM and Wildonger J: A CRISPR view of development. Genes Dev. 28:1859–1872. 2014. View Article : Google Scholar : PubMed/NCBI
9	Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 337:816–821. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hryhorowicz M, Lipinski D, Zeyland J and Slomski R: CRISPR/Cas9 immune system as a tool for genome engineering. Arch Immunol Ther Exp (Warsz). 65:233–240. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lopes R, Korkmaz G and Agami R: Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers. Nat Rev Mol Cell Biol. 17:597–604. 2016. View Article : Google Scholar : PubMed/NCBI
12	Jiang W, Bikard D, Cox D, Zhang F and Marraffini LA: RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. 31:233–239. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
14	Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR and Joung JK: Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 31:227–229. 2013. View Article : Google Scholar : PubMed/NCBI
15	DiCarlo JE, Norville JE, Mali P, Rios X, Aach J and Church GM: Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res. 41:4336–4343. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bassett AR, Tibbit C, Ponting CP and Liu JL: Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep. 4:220–228. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F and Jaenisch R: One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 153:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
18	Li D, Qiu Z, Shao Y, Chen Y, Guan Y, Liu M, Li Y, Gao N, Wang L, Lu X, et al: Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 31:681–683. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yang D, Xu J, Zhu T, Fan J, Lai L, Zhang J and Chen YE: Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. J Mol Cell Biol. 6:97–99. 2014. View Article : Google Scholar : PubMed/NCBI
20	Essletzbichler P, Konopka T, Santoro F, Chen D, Gapp BV, Kralovics R, Brummelkamp TR, Nijman SM and Bürckstümmer T: Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res. 24:2059–2065. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 8:2281–2308. 2013. View Article : Google Scholar : PubMed/NCBI
22	Brinkman EK, Chen T, Amendola M and van Steensel B: Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42:e1682014. View Article : Google Scholar : PubMed/NCBI
23	Nemudryi AA, Valetdinova KR, Medvedev SP and Zakian SM: TALEN and CRISPR/Cas genome editing systems: Tools of discovery. Acta Naturae. 6:19–40. 2014.PubMed/NCBI
24	Boettcher M and McManus MT: Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell. 58:575–585. 2015. View Article : Google Scholar : PubMed/NCBI
25	Roschke AV and Rozenblum E: Multi-layered cancer chromosomal instability phenotype. Front Oncol. 3:3022013. View Article : Google Scholar : PubMed/NCBI
26	Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y and Fausto N: Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology. 47:2078–2088. 2008. View Article : Google Scholar : PubMed/NCBI
27	Reichl P, Dengler M, van Zijl F, Huber H, Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W, et al: Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology. 61:930–941. 2015. View Article : Google Scholar : PubMed/NCBI
28	Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, et al: Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 137:385–394. 2015. View Article : Google Scholar : PubMed/NCBI
29	Petz M, Them N, Huber H, Beug H and Mikulits W: La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic Acids Res. 40:290–302. 2012. View Article : Google Scholar : PubMed/NCBI
30	Hwang HJ, Kim GJ, Lee GB, Oh JT, Chun YH and Park SH: A comprehensive karyotypic analysis on Korean hepatocellular carcinoma cell lines by cross-species color banding and comparative genomic hybridization. Cancer Genet Cytogenet. 141:128–137. 2003. View Article : Google Scholar : PubMed/NCBI
31	Dor I, Namba M and Sato J: Establishment and some biological characteristics of human hepatoma cell lines. Gan. 66:385–392. 1975.PubMed/NCBI
32	Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, et al: Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov. 6:914–929. 2016. View Article : Google Scholar : PubMed/NCBI
33	Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, et al: CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov. 6:900–913. 2016. View Article : Google Scholar : PubMed/NCBI
34	Hastings RJ and Franks LM: Cellular heterogeneity in a tissue culture cell line derived from a human bladder carcinoma. Br J Cancer. 47:233–244. 1983. View Article : Google Scholar : PubMed/NCBI
35	Rauch BJ, Silvis MR, Hultquist JF, Waters CS, McGregor MJ, Krogan NJ and Bondy-Denomy J: Inhibition of CRISPR-Cas9 with bacteriophage proteins. Cell. 168(150–158): e1102017.
36	Pawluk A, Amrani N, Zhang Y, Garcia B, Hidalgo-Reyes Y, Lee J, Edraki A, Shah M, Sontheimer EJ, Maxwell KL and Davidson AR: Naturally occurring off-switches for CRISPR-Cas9. Cell. 167:1829–1838.e9. 2016. View Article : Google Scholar : PubMed/NCBI
37	Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N and Ranganathan S: Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 208:44–53. 2015. View Article : Google Scholar : PubMed/NCBI
38	Kim S, Kim D, Cho SW, Kim J and Kim JS: Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24:1012–1019. 2014. View Article : Google Scholar : PubMed/NCBI